A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety and efficacy of 60mg ticagrelor plus 100mg Aspirin to
prevent major adverse cardiovascular and cerebrovascular events in one years after
drug-eluting stents implantation for Chinese ACS patients compared with 90mg ticagrelor plus
100mg Aspirin
Phase:
Phase 4
Details
Lead Sponsor:
Shanghai Tong Ren Hospital
Collaborators:
Fudan University Shanghai Jiao Tong University School of Medicine